Matched unrelated bone marrow transplant for severe combined immunodeficiency
- 65 Downloads
Severe combined immunodeficiency (SCID) is a lethal disease unless allogeneic bone marrow transplantation (BMT), preferably from a family related HLA identical donor (RID) is given. Previously, some patients received HLA-mismatched related donors (MMRD) BMT, which often resulted in slow immune reconstitution and variable survival. Alternatively, HLA-matched unrelated donors (MUD) BMT have been suggested. Recently, we have directly compared outcome of patients with SCID who received either MMRD or MUD BMT. Survival after MUD BMT was significantly better than after MMRD BMT. Patients who received MUD BMT also had better engraftment of donor cells and immune reconstitution. Recent reports from other centers confirm these results finding that MUD BMT provides excellent survival and better immune reconstitution for patients with SCID. In conclusion, MUD BMT appears vastly superior to MMRD BMT and should be offered as first choice of treatment for patients with SCID when RID is unavailable.
KeywordsBone marrow transplant Matched unrelated severe combined immunodeficiency T+ SCID
- 6.Caillat-Zucman S, Le Deist F, Haddad E, et al. Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-centre comparative analysis of genoidentical, haploidentical or unrelated donors. Bone Marrow Transplant 2004;33:1089–95.PubMedCrossRefGoogle Scholar
- 17.Roifman CM. Studies of Patients’ Thymi aid in the discovery and characterization of immunodeficiency in humans. In: Koretzky G, Monroe J, editors. Immunological reviews. Vol. 203. Singapore: Blackwell Munksguard; 2005. p. 143–55.Google Scholar
- 32.Drobyski WR, Klein J, Fmomeberg N, et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 2002;99:806–14.PubMedCrossRefGoogle Scholar